Application of inhibitor of Galphai3 gene in preparation of medicine for preventing and / or treating bladder cancer

Through inhibitors or knockout technology targeting the Gαi3 gene, the problems of different therapeutic effects and drug resistance of bladder cancer are solved, and new biomarkers and diagnostic methods are provided to significantly inhibit the proliferation and migration of bladder cancer cells and promote the Apoptosis enhances the effectiveness of treatment and diagnosis.

CN119055774APending Publication Date: 2024-12-03CHANGZHOU NO 2 PEOPLES HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411206872.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing targeted treatment methods for bladder cancer are different due to the genetic heterogeneity of bladder cancer and the complex tissue microenvironment, resulting in different therapeutic effects and high drug resistance, and lack of effective biomarkers and therapeutic targets.

Method used

Develop inhibitors of the Gαi3 gene, targeting silencing or knocking out the Gαi3 gene through shRNA or CRISPR/Cas9 technology, for the preparation of drugs for preventing and treating bladder cancer, and for exploring the application of Gαi3 as a biomarker and diagnostic reagent.

Benefits of technology

In bladder cancer cells, targeting Gαi3 can significantly inhibit cell proliferation, migration and invasion, induce apoptosis, reduce the activity of the Akt-mTOR pathway, and provide new therapeutic strategies and diagnostic directions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055774A_ABST
    Figure CN119055774A_ABST
Patent Text Reader

Abstract

The invention discloses application of a G alpha i3 gene inhibitor in preparation of a medicine for preventing and / or treating bladder cancer, and belongs to the field of medicine. By analyzing the existing single cell sequencing data, the overexpression of the G alphai3 in the bladder cancer epithelial cells is found. Meanwhile, the expression of the G alpha i3 is up-regulated in bladder cancer tissues and various bladder cancer cells of local treatment patients. In bladder cancer cells, proliferation, migration and invasion of the cells can be inhibited by targeting shRNA to silence the G alpha i3, and activation of caspase-apoptosis is induced. The CRISPR / Cas9 technology is utilized to knock out the Galphai3, so that a remarkable anti-cancer effect can be obtained, and the overexpression of the Galphai3 promotes the proliferation, migration and invasion of primary bladder cancer cells. The discovery provides a new insight for the effect of the G alphai3 in bladder cancer progression, indicates that the G alphai3 can become a new bladder cancer biomarker and a treatment target, and provides a new direction for diagnosis and treatment of bladder cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to the use of a Gαi3 gene inhibitor in the preparation of a medicine for preventing and / or treating bladder cancer. Background Art

[0002] Bladder cancer remains a common malignancy in the general population, and the long-term survival rate of patients with advanced or metastatic bladder cancer remains significantly low. The main treatment methods for non-muscle-invasive bladder cancer include complete tumor resection combined with intravesical vaccination, chemotherapy, and maintenance immunotherapy. For muscle-invasive bladder cancer, treatment options mainly include radical cystectomy and neoadjuvant chemotherapy, as well as other treatment methods. Recently, immunotherapy has become a viable treatment option, especially for patients who show resistance to first-line chemotherapy. The genetic heterogeneity of bladder cancer, coupled with its complex tissue microenvironment, highlights the complexity of the disease. A comprehensive understanding of the molecular biological basis of bladder cancer is imperative for the development of new molecular targeted therapeutic strategies.

[0003] Current targeted therapies for bladder cancer focus on disrupting specific molecular pathways and genetic alterations that are intrinsic to bladder cancer. Fibroblast growth factor receptor (FGFR) inhibitors, including erdafitinib, target FGFR mutations that are prevalent in bladder cancer. Immune checkpoint inhibitors, including pembrolizumab and atezolizumab, inhibit the PD-1 / PD-L1 pathway, thereby enhancing the immune system's ability to fight cancer cells. HER2 inhibitors, such as trastuzumab, are used in tumors that overexpress HER2, while vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab, are designed to block tumor angiogenesis. Mammalian target of rapamycin (mTOR) inhibitors, including everolimus, target pathways that are key to cancer cell proliferation and survival. Antibody-drug conjugates that target nectin-4 deliver cytotoxic drugs directly to cancer cells, minimizing collateral damage to healthy tissue. Poly (ADP ribose) polymerase (PARP) inhibitors exploit DNA repair defects in cancer cells to induce cell death. Current targeted therapies for bladder cancer face limitations due to the genetic heterogeneity of bladder cancer, which leads to variable patient responses and the development of drug resistance, thus reducing long-term efficacy. Therefore, it is important to identify other key targets.

[0004] The inhibitory heterotrimeric G protein (Gαi) family has three distinct subunits: Gαi1, Gαi2, and Gαi3. Gαi proteins are known to bind to G protein-coupled receptors (GPCRs) and play an important role in downregulating adenylate cyclase (AC) activity, thereby reducing intracellular cyclic adenosine monophosphate (cAMP) levels. Recent studies have highlighted that Gαi1 and Gαi3 are key to signal transduction by various receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), keratinocyte growth factor receptor (KGFR), stem cell factor (SCF) receptor c-kit, brain-derived neurotrophic factor (BDNF) receptor TrkB, and vascular endothelial growth factor receptor 2 (VEGFR2). Gαi proteins are essential in mediating oncogenic signaling cascades, including the Akt-mTOR pathway. This finding highlights their critical role in signaling that promotes tumor initiation and progression.

[0005] In addition to their association with receptor tyrosine kinases (RTKs), Gαi1 and Gαi3 have been found to bind to a variety of non-RTK receptors. These receptors include leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4) for R-spondin3 (RSPO3), CD146 for Netrin-1, interleukin-4 (IL-4) receptor for lipopolysaccharide (LPS), and toll-like receptor 4 (TLR4) for lipopolysaccharide (LPS). Through these interactions, Gαi proteins play an important role in the activation of the Akt-mTOR signaling pathway, highlighting their key role as oncogenic drivers and their potential as targets for cancer therapy. Recent studies have shown that Gαi proteins are frequently overexpressed in a variety of human cancers, highlighting their important functions in tumorigenesis and progression. However, there are currently no reports on the relationship between the expression pattern of Gαi3 protein and the mechanism of action of the occurrence and development of bladder cancer. Therefore, the present invention is dedicated to exploring the expression pattern and functional importance of Gαi3 in bladder cancer, aiming to provide comprehensive insights into its use as a biomarker and target for therapeutic strategies. Summary of the invention

[0006] The purpose of the present invention is to provide an inhibitor of the Gαi3 gene for use in the preparation of a drug for preventing and / or treating bladder cancer, so as to solve the problems existing in the above-mentioned prior art. The Gαi3 gene is highly expressed in bladder cancer tissues. By silencing or knocking out the Gαi3 gene, the anti-bladder cancer effect can be significantly improved, which provides a new biomarker and treatment strategy for the diagnosis and treatment of bladder cancer.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The present invention provides the use of a Gαi3 gene inhibitor in preparing a medicine for preventing and / or treating bladder cancer.

[0009] Preferably, the inhibitor of the Gαi3 gene is selected from shRNA specific to the Gαi3 gene.

[0010] Preferably, the drug comprises a pharmaceutically acceptable carrier and an effective amount of an active ingredient, and the active ingredient is an inhibitor of the Gαi3 gene.

[0011] The present invention also provides a drug for preventing and / or treating bladder cancer, comprising a pharmaceutically acceptable carrier and an effective amount of a Gαi3 gene inhibitor, wherein the Gαi3 gene inhibitor is selected from a Gαi3 gene-specific shRNA.

[0012] The present invention also provides the use of the Gαi3 gene as a bladder cancer biomarker in the preparation of a bladder cancer diagnostic kit or a diagnostic reagent.

[0013] Preferably, the diagnostic kit or diagnostic reagent comprises a primer pair for detecting the Gαi3 gene.

[0014] The present invention also provides a kit for diagnosing bladder cancer, which comprises a reagent for detecting the Gαi3 gene.

[0015] Preferably, the reagents include a primer pair for amplifying the Gαi3 gene.

[0016] The present invention also provides the use of a reagent for detecting the expression amount of the Gαi3 gene in preparing an auxiliary diagnostic reagent for bladder cancer. The reagent for detecting the expression amount of the Gαi3 gene comprises a primer pair for detecting the Gαi3 gene.

[0017] The present invention also provides an in vitro non-therapeutic method for inhibiting bladder cancer cells, comprising the following steps: culturing bladder cancer cells in the presence of an inhibitor of the Gαi3 gene, thereby inhibiting the proliferation and growth of bladder cancer cells; the inhibitor of the Gαi3 gene is selected from shRNA specific to the Gαi3 gene.

[0018] The present invention discloses the following technical effects:

[0019] In the present invention, silencing Gαi3 by targeted shRNA in bladder cancer cells can inhibit cell proliferation, migration and invasion, and induce the activation of caspase-apoptosis. Using CRISPR / Cas9 technology to knock out (KO) Gαi3 can obtain a significant anti-cancer effect. Conversely, overexpression of Gαi3 promotes the proliferation, migration and invasion of primary bladder cancer cells. Gαi3 promotes the Akt-mTOR pathway in bladder cancer cells. Silencing or knocking out Gαi3 can reduce the phosphorylation levels of Akt and S6K, while overexpression of Gαi3 can increase their phosphorylation levels. The anti-cancer effect of gαi3 shRNA is reduced by reactivating Akt-mTOR by constitutively active Akt1 mutants. In vivo, silencing Gαi3 can significantly inhibit the growth of primary bladder cancer cells of subcutaneous xenografts in nude mice, inactivate the Akt-mTOR pathway, and induce cell apoptosis. The present invention provides new insights into the role of Gαi3 in the progression of bladder cancer, indicating that Gαi3 may become a new bladder cancer biomarker and therapeutic target, providing a new direction for the diagnosis and treatment of bladder cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1Correlation of Gαi3 overexpression with key clinical parameters in bladder cancer; (AH) Analysis of the TCGA-BLCA cohort shows Gαi3 expression in bladder cancer tissue (“tumor”) and normal lung tissue (“normal”) of selected patients. mRNA transcription level; (I) Kaplan-Meier survival curves of bladder cancer patients with low Gαi3 expression (blue) and high Gαi3 expression (red); (JK) Subgroup Kaplan-Meier survival analysis results of papillary and non-papillary bladder cancer patients, respectively; (L) Receiver operating characteristic (ROC) curves to evaluate the predictive value of Gαi3 expression in bladder cancer patients; (M) ROC curves analyzed the predictive value of Gαi3 expression in distinguishing high-grade from low-grade bladder cancer; (N) ROC curves analyzed the predictive value of Gαi3 expression in diagnosing papillary and non-papillary bladder cancer; "TPM" stands for transcripts per million, AUC stands for area under the curve (AUC), "CI" stands for confidence interval, "HR" stands for hazard rate, "TPR" stands for true positive rate, "FPR" stands for false positive rate, "PD" stands for progressive disease, "SD" stands for stable disease, "PR" stands for partial response, and "CR" stands for complete response; *p<0.05, **p<0.05, ***p<0.001;

[0022] Figure 2 Single-cell sequencing was used to detect the expression of Gαi3 in bladder cancer epithelial cells; (A) Cell annotation results obtained from bladder cancer single-cell data (GSE222315); (B) UMAP diagram shows the expression distribution of Gαi3 in bladder cancer (BLCA) and control normal bladder samples ("NORM"); (C) Dot plot shows the expression distribution of Gαi3 in bladder cancer (BLCA) and control normal bladder samples ("NORM"); (D) Violin plot highlights the expression levels of Gαi3 in normal ("NORM") and bladder cancer ("BLCA") epithelial cell subsets; (E) UMAP diagram shows Gαi3 + and Gαi3 - Expression distribution of bladder cancer epithelial cells; (F, G) are respectively for Gαi3 + and Gαi3 - GO functional enrichment analysis and KEGG pathway enrichment analysis of differentially expressed genes in bladder cancer epithelial cells;

[0023] Figure 3To detect the expression of Gαi3 in human bladder cancer tissues and cells; (AB) The expression of Gαi3 mRNA and protein in bladder cancer tissues (T) and adjacent normal bladder tissues (N) of 12 patients who underwent primary tumor resection were analyzed; (C) The statistical results of Figure B; (D) Representative Gαi3 IHC staining images in cancer tissues and normal tissues and the IHC results to calculate the scoring results of all 12 pairs of tissues; (E, F) Detection of Gαi3 Expression of mRNA and protein in primary (priBlCa-1, priBlCa-2, priBlCa-3) and immortalized (T24) bladder cancer cells and bladder epithelial cells (priBEC-1 and priBEC-2); data are expressed as mean ± standard deviation (SD); in AD, each group includes 12 patient tissue sets (n = 12); in E and F, n = 5, representing 5 biological replicates; *p < 0.05 compared with "N" tissue / priBEC-1 cells; scale bar = 100 μm;

[0024] Figure 4 To detect whether Gαi3 shRNA has anti-tumor effect in bladder cancer cells; (A) qPCR was used to detect the expression levels of Gαi1, Gαi2 and Gαi3 mRNA; (B) Western Blotting was used to detect the expression levels of Gαi1, Gαi2 and Gαi3 proteins; (C) The results of priBlCa-1 cell viability detection after knocking out Gαi3; (D) The proportion of EdU-stained cell nuclei was used to detect cell proliferation; (E) "Transwell" assay was used to detect cell migration; (F) "Transwell" assay was used to detect cell invasion; (G) qPCR was used to detect the expression level of Gαi3 mRNA in primary and immortalized bladder cancer cells; (H) qPCR was used to detect Gαi1 mRNA expression levels in primary and immortalized bladder cancer cells; (I) Effects of Gαi3 knockdown on cell proliferation in primary bladder cancer cells and T24 cell lines; (J) "transwell" assay to verify the effects on cell migration in primary bladder cancer cells and T24 cell lines; (K) Effects of shGαi3-S3 transduction of primary bladder epithelial cells on Gαi3 mRNA expression; (L) Effects of shGαi3-S3 transduction of primary bladder epithelial cells on Gαi1 mRNA expression; (M) EdU assay to verify the effects of shGαi3-S3 transduction of primary bladder epithelial cells on cell proliferation;

[0025] (N) Effect of shGαi3-S3 transduction on cell viability of primary bladder epithelial cells; parental control cells are indicated as “Pare”; data are expressed as mean ± standard deviation (SD); N = 5, indicating 5 biological replicates; *p < 0.05 indicates statistical significance compared with the “shC” group; no statistical significance (p > 0.05) compared with the “NS” group; each experiment was repeated 5 times, and the results were consistent; scale bar = 100 μm;

[0026] Figure 5 Gαi3 shRNA induced apoptosis and activation of bladder cancer cells; primary (priBlCa-1, priBlCa-2, priBlCa-3) and constructed T24 human bladder cancer cells and bladder epithelial cells (priBEC-1 and priBEC-2) were stably transduced with Gαi3-specific lentiviral shRNA (shGαi3-S1, shGαi3-S2 or shGαi3-S3 with different sequences, respectively) or scramblecontrol shRNA ("shC") for 72 hours, and then the activity of caspase-3 (A and H), the expression level of apoptosis-related proteins (B), the content of histone-bound DNA (ELISA, C), the level of cytoplasmic cytochrome C (ELISA, D) and mitochondrial depolarization (JC-1 staining, E) were detected;

[0027] Figure 6 To quantify Gαi3shRNA-induced apoptosis by nuclear TUNEL staining (A, B, and C) and Annexin V FACS assay (D); parental control cells are indicated by "Pare"; data are expressed as mean ± standard deviation (SD); N = 5, indicating 5 biological replicates; *p < 0.05 indicates statistical significance, and "NS" indicates no statistical significance compared with the "shC" group. There is a statistically significant difference (p> 0.05); each experiment was repeated 5 times to obtain consistent results; scale bar = 100 μm;

[0028] Figure 7Effects of Gαi3 gene knockout on the progression of bladder cancer cells; (A) Western Blotting was used to detect the expression levels of Gαi1, Gαi2 and Gαi3 proteins in bladder cancer cells; (B) Evaluation of cancer cell proliferation (measured by the proportion of EdU-positive nuclei); (C, D) Evaluation of cancer cell migration and invasion (measured by the "Transwell" method); (E) Evaluation of mitochondrial depolarization in cancer cells (analyzed by JC-1 staining); (F) Evaluation of cancer cell apoptosis (measured by the proportion of TUNEL-positive nuclei); (G ... Blotting method was used to detect the expression levels of Gαi1 and Gαi3 proteins in bladder epithelial cell lines; (H, I) evaluated the viability and proliferation of bladder epithelial cells, respectively; data are expressed as mean ± standard deviation (SD); N = 5 represents 5 biological replicates; compared with the "koC" group, *p < 0.05 indicates a statistically significant difference; compared with the "NS" group, p > 0.05 indicates no statistically significant difference; each experiment was repeated 5 times, and the results were consistent; scale bar = 100 μm;

[0029] Figure 8 Figure 3 The relevance of Gαi3 overexpression on the oncogenic behavior of bladder cancer cells. PriBlCa-1 primary bladder cancer cells were transduced with lentiviral Gαi3 overexpression constructs ("oeGαi3-stb slc1" and "oeGαi3-stb slc2", representing two stable cell lines) or empty vector ("Vec"). The mRNA and protein expression levels of Gαi1, Gαi2, and Gαi3 were then assessed (A and B). After the indicated culture periods, cell proliferation was assessed using EdU staining (C), while in vitro migration (D) and invasion (E) of cells were measured. Similarly, primary bladder cancer cells (priBlCa-2 and priBlCa-3) and the established T24 human bladder cancer cell line were transduced with lentiviral Gαi3 overexpression constructs ("oeGαi3-stb slc2"). i3”) or empty vector (“Vec”) were transduced, and the mRNA expression levels of Gαi1 and Gαi3 were analyzed (F and G); after a certain culture time, cell proliferation (H) and in vitro cell migration (I) were also evaluated; data are presented as mean ± standard deviation (SD); N = 5 represents 5 biological replicates; compared with the “Vec” group, *p < 0.05 indicates a statistically significant difference; compared with the “NS” group, there was no statistically significant difference (p> 0.05); each experiment was repeated 5 times, and the results were consistent; scale bar = 100 μm;

[0030] Fig. 9Effect of Gαi3 on activation of Akt-mTOR in bladder cancer cells; priBlCa-1 primary bladder cancer cells with Gαi3-specific lentiviral shRNA (shGαi3-S1, shGαi3-S2, or shGαi3-S3, representing different sequences), a scramble control shRNA ("shC"), a Cas9 expression construct plus CRISPR / Cas9-gαi3-ko-puro constructs ("koGαi3-C1" and "koGαi3-C2", two stable colonies), a CRISPR / Cas9 empty vector ("koC"), a lentiviral Gαi3 overexpression construct ("oeGαi3-stb slc1" and "oeGαi3-stb slc2", representing two stable cell lines) or empty vector ("Vec"), and the expression of the listed proteins is shown (AC); priBlCa-1 cells expressing shGαi3-s3 were stably transduced with or without constitutively active S473D mutant Akt1 (caAkt1); the expression levels of the indicated proteins are shown (D);

[0031] Fig.10 Transduced cells were cultured for the indicated time and cell proliferation was assessed using EdU-nuclear staining (A), migration was assessed using “Transwell” (B), and apoptosis was assessed using TUNEL-nuclear staining (C); data are presented as mean ± standard deviation (SD); N = 5 represents 5 biological replicates; *p < 0.05 indicates statistical significance compared with “shC” / “koC” / “Vec” cells; #p < 0.05; each experiment was repeated 5 times to obtain consistent results; scale bar = 100 μm;

[0032] Fig.11Effects of Gαi3 silencing on the growth of primary bladder cancer xenografts in nude mice; (A) Volume of priBlCa-1 xenografts; (B) Evaluation of the daily growth rate of priBlCa-1 xenografts; (C) Xenografts were surgically removed and their weights were measured on day 52; (D) Body weight of priBlCa-1 xenografts; (EG, J) Protein and mRNA expression analysis results of tissue lysates of harvested xenograft tissues; (H, I) Expression of xenografts in priBlCa-1 xenografts, respectively. The sections were subjected to IHC staining to detect p-Akt (Ser-473) and nuclear Ki-67; (K) TUNEL / DAPI fluorescence staining results; data are expressed as mean ± standard deviation (SD); compared with the "shC" group, the difference was statistically significant (*P<0.05), while the difference in the "NS" group was not statistically significant (P>0.05); the sample size of AD was 10 mice per group; in EK, each xenograft was cut into 5 pieces and analyzed separately; scale bar = 100 μm. DETAILED DESCRIPTION

[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0034] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0038] Example 1

[0039] 1. Experimental Materials

[0040] (1) Reagents and chemicals: Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Co., Ltd. (Kumamoto, Japan). Puromycin, polybrene, culture medium, antibiotics, serum, and RNA reagents were from Sigma-Aldrich (St. Louis, MO). EdU, DAPI, TUNEL, JC-1, and Annexin V / PI fluorescent dyes were purchased from Invitrogen Thermo-Fisher (Shanghai, China). All antibodies, viral constructs, and mRNA primers were provided by Dr. Cao.

[0041] (2) Human tissue: 12 patients aged 65-76 years with muscle-invasive bladder cancer (t2-t4a, N0, M0) who underwent surgery were included in the study. The cancer tissue and adjacent normal bladder tissue were carefully separated under a microscope according to the reference “A first-in-class TIMM44 blocker inhibits bladder cancer cell growth”. Tissue lysates were subjected to Western Blotting and qPCR detection. All patients were treated at the Changzhou Second People's Hospital Affiliated to Nanjing Medical University, and informed consent was obtained. The study protocol was approved by the Ethics Review Committee of the Changzhou Second People's Hospital Affiliated to Nanjing Medical University and complied with the Declaration of Helsinki.

[0042] (3) T24 immortalized bladder cancer cells were obtained from Shanghai Institute of Biological Sciences and cultured in DMEM containing 8% fetal bovine serum, gentamicin, penicillin / streptomycin, L-glutamine, and HEPES at 37°C and 5% CO 2For primary human cells, primary cancer tissue and adjacent normal epithelial tissue were isolated, rinsed with PBS, minced, and digested with type I collagenase and DNase. The resulting single-cell suspension was filtered through a 70 μm filter, collected, washed, and resuspended in culture medium. As previously reported in the literature “A first-in-class TIMM44 blocker inhibits bladder cancer cell growth”, primary bladder cancer cells were from three patients (priBlCa-1, priBlCa-2, priBlCa-3), and primary epithelial cells were from two patients (priBEC-1, priBEC-2). Cell phenotype validation included detection of mycoplasma, microbial contamination, STR profile analysis, population doubling time, and morphological assessment every 8 weeks. The protocol was approved by the Ethics Review Committee of Changzhou Second People's Hospital Affiliated to Nanjing Medical University and followed the Declaration of Helsinki.

[0043] 2. Experimental methods

[0044] 2.1 Western Blotting

[0045] Protein lysates (30 μg) were isolated from cells and tissues and then transferred to PVDF blots. The membranes were blocked and incubated with the designated primary antibodies overnight at 4°C, followed by incubation with secondary antibodies for 45 min at room temperature. Protein bands were visualized using an enhanced chemiluminescence (ECL) system and quantified using ImageJ software.

[0046] 2.2qPCR detection

[0047] RNA was extracted from cells and tissues using TRIzol, converted into cDNA using the Takara kit, and analyzed by qPCR using SYBR Green PCR Master Mixes on the ABI-7900 system. GAPDH was used as an internal reference gene, 2 -ΔΔCt Methods The relative gene expression was determined. The primers were provided by Dr. Cao, and the specific sequences can be found in the literature "Identification of Galphai3 as a novel molecular therapeutic target of cervical cancer" and "Identification of Galphai3 as a promising target for osteosarcoma treatment".

[0048] 2.3 Silencing of Gαi3 by shRNA

[0049] Dr. Cao from Soochow University provided three different shRNAs targeting human Gαi3 (shGαi3-S1, shGαi3-S2, and shGαi3-S3) (references “Identification of Galphai3 as a novel molecular therapeutic target of cervical cancer” and “Identification of Galphai3 as a promising target for osteosarcoma treatment”). The shRNA sequences were transduced into the empty vector GV369, and then transferred into bladder cancer cells or epithelial cells to reconstruct the recombinant cells. The recombinant cells were then cultured in a medium containing FBS and polystyrene to enhance transduction. The cells were infected with lentivirus for 40 hours at an MOI of 10. After infection, the cells were placed in a medium containing puromycin for 10 days, and stable colonies were screened. qPCR and Western Blotting were used to verify the knockout efficiency of Gαi3.

[0050] 2.4 Overexpression of Gαi3

[0051] In order to overexpress Gαi3, the present invention uses a lentiviral vector containing the Gαi3 gene, which is still provided by Dr. Cao (reference "Identification of Galphai3 as a novel molecular therapeutic target of cervical cancer" and "Identification of Galphai3 as a promising target for osteosarcoma treatment"). Bladder cancer cells are grown in a culture medium containing FBS and polystyrene to promote viral transduction. These cells were infected with Gαi3 lentivirus for 40 hours at an MOI of 10. After infection, the cells were cultured in a culture medium containing puromycin for 7 to 8 days, and cells that stably overexpressed gαi3 were screened. The expression of Gαi3 in these cells was confirmed by qPCR and Western Blotting.

[0052] 2.5Gαi3 knockout

[0053] Bladder cancer cells with a confluency of 50-60% were cultured in complete medium containing polybrene and infected with lentivirus expressing cas9 to obtain stable bladder cancer cells. These cells were then transduced with CRISPR / Cas9-Gαi3-KO lentivirus containing sgRNA targeting Gαi3. After puromycin selection, cells were isolated into 96-well plates at the single-cell level. Sequencing around the target site and Western Blotting confirmed Gαi3 knockout. Subsequently, two stable single-cell-derived Gαi3 knockout colonies, koGαi3-C1 and koGαi3-C2, were established, both showing complete knockout of Gαi3 protein. Control cells were infected with CRISPR / cas9 empty vector lentivirus ("koC") as described above. Gαi3 KO in Epithelial Cells Cas9-expressing bladder epithelial cells (priBEC-1 and priBEC-2) were constructed by the same procedure, containing the CRISPR / Cas9-Gαi3-ko-puro construct (“koGαi3”) or the control CRISPR / Cas9 empty vector (“koC”), and finally stable single-cell clones were obtained.

[0054] 2.6 CCK-8 activity assay

[0055] The cells (3×10 3 Cells / well) were placed in a 96-well plate and cultured for a specified time. CCK-8 reagent (15 μL / well) was added for 2 h, and the absorbance at 450 nm was measured using an ELISA reader.

[0056] 2.7 Nuclear TUNEL / EdU staining

[0057] Treated cancer cells or epithelial cells were seeded on coverslips in 24-well plates and cultured for a specific time. Cells were fixed with 4% formaldehyde-PBS for 12 minutes at room temperature and permeabilized with 0.1% TritonX-100 in PBS for 6 minutes. Cell nuclei were stained with TUNEL, EdU or DAPI dyes. Fluorescence images were taken under a fluorescence microscope.

[0058] 2.8 Transwell assay

[0059] Transwell culture dishes (Corning, NY, US) were used, and 150 μL of cell suspension (10,000 cells) was added to each dish. The lower chamber contained 600 μL of culture medium containing 10% FBS. After incubation for 24 h, non-migrated cells were removed, and migrated cells were stained with 0.25% crystal violet for 10 min, washed with PBS, and photographed. For in vitro cell invasion assays, Transwell inserts were coated with Matrigel (100 μg / cm 2 , Sigma).

[0060] 2.9 Caspase-3 activity assay

[0061] Total cell or tissue lysates were analyzed using a Caspase Fluorescence Detection Kit (BD Bioscience, Suzhou, China). Caspase-3 activity was determined by fluorescence assay using the substrate Ac-DEVD-AMC.

[0062] 2.10 Flow cytometry

[0063] Bladder cancer cells or epithelial cells were centrifuged, resuspended, and stained with Annexin V-APC (5 μL) and / or propidium iodide (PI, 5 μL) (Sigma). Cell apoptosis was detected using a CytoFLEX flow cytometer (Beckman, Shanghai, China).

[0064] 2.11 Cytochrome C detection

[0065] Cytochrome C enzyme-linked immunosorbent assay was performed using a commercial kit (Biyuntian, Wuxi, China). Cytosolic lysate was added to a 96-well plate to block nonspecific binding sites. The plate was then washed and a cytochrome C-specific primary antibody was added, followed by an HRP-conjugated secondary antibody. The colorimetric reaction was initiated with TMB substrate solution. The absorbance was measured at 450 nm using a microplate reader.

[0066] 2.12 Mitochondrial depolarization detection (ΔΨm)

[0067] Mitochondrial membrane potential (MMP) reduction was assessed using JC-1 staining (Invitrogen). After treatment, cells were stained with JC-1 dye (4.0 μg / mL) and excess dye was washed away with water. The green fluorescence intensity of JC-1 was measured under a 490 nm fluorescence microscope, indicating a reduction in MMP (ΔΨm).

[0068] 2.13 Constitutively active mutant Akt1 (caAkt1)

[0069] According to the references “A first-in-class TIMM44 blocker inhibits bladder cancer cell growth” and “A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo”, bladder cancer cells were infected with lentivirus carrying a constitutively active S473D Akt1 mutant (“caAkt1”) or an empty vector. Cells stably expressing ca-Aktt1 were selected with puromycin.

[0070] 2.14 Xenotransplantation experiments

[0071] Stable priBlCa-1 cells expressing Gαi3 shRNA ("shGαi3-S3") or control shRNA ("shC") were subcutaneously injected into nude mice of both sexes, 5 to 6 weeks old, 18 to 19 grams. Each mouse received 5 million cells. There were 10 mice in each group (n=10). Observation began on the 10th day (day 10) after the initial inoculation of cells. From day 10 to day 52, the volume of priBlCa-1 xenografts and the body weight of mice were measured and recorded every 6 days. The daily growth rate of priBlCa-1 xenografts was evaluated. On day 52, the xenografts were surgically removed and their weights were measured. For further analysis, two xenografts were selected from each group (designated "#1" and "#2"), and tissue lysates of these harvested xenograft tissues were subjected to protein and mRNA expression analysis. In addition, sections of xenografts were subjected to immunohistochemistry (IHC) staining for p-Akt (Ser-473) or nuclear Ki-67, and TUNEL / DAPI fluorescence staining.

[0072] IHC staining: Tumors were fixed, embedded in paraffin, and sectioned at 4 μm. Sections were dewaxed, rehydrated, and antigen retrieved. After blocking, sections were incubated with primary antibodies, followed by secondary antibodies, and detected using DAB. Sections were stained with TUNEL (Biyuntian, Wuxi, China) and counterstained with DAPI after washing to visualize cell nuclei. Sections were fixed with antifading medium and observed under a fluorescence microscope. All animal experiments were approved by the IACUC and the Ethics Committee of Nanjing Medical University.

[0073] 2.15 Statistical analysis

[0074] All in vitro experiments were blindly grouped and repeated 5 times. Data that met the normal distribution were expressed as mean ± standard deviation. SPSS version 23.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. The independent sample t test was used for comparison between two groups, and the one-way analysis of variance with Scheffe' and Tukey's test was used for comparison between multiple groups. P < 0.05 was considered statistically significant.

[0075] 3. Results and analysis

[0076] 3.1 Gαi3 overexpression is associated with key clinical parameters of bladder cancer

[0077] The present invention first queries The Cancer Genome Atlas bladder cancer (TCGA-BLCA) database to retrieve the expression data of Gαi3 (GNAI3). The analysis shows that the number of Gαi3 mRNA transcripts in bladder cancer tissue ("Tumor") is significantly higher than that in normal bladder tissue ("normal") ( Figure 1 In addition, paired data also confirmed this finding, showing that Gαi3 was expressed at a higher level in bladder cancer tissue (“Tumor”) compared with paired normal tissue ( Figure 1 Middle B). The expression of Gαi3 in high-grade bladder cancer tissues is higher than that in low-grade bladder cancer tissues ( Figure 1 In addition, the expression of Gαi3 in bladder cancer tissues was significantly higher in cases of progressive disease (PD), but relatively lower in cases of complete remission (CR) ( Figure 1 In addition, Gαi3 expression was found to be decreased in bladder cancer tissues after radiotherapy ( Figure 1 Middle E).

[0078] Further subgroup analysis showed that Gαi3 expression was significantly higher in bladder tissue of patients who had died of the disease (“Dead”) compared with those who were still alive (“alive”). Figure 1 In addition, the present invention also found that the overexpression of Gαi3 in bladder cancer tissue is associated with a shorter progression-free interval (PFI) ( Figure 1 medium G) and lower disease-specific survival (DSS) ( Figure 1 These findings suggest that elevated levels of Gαi3 may be associated with poor clinical outcomes in bladder cancer patients, highlighting its potential as a prognostic biomarker.

[0079] In fact, Kaplan Meier survival analysis of the TCGA-BLCA database showed that Gαi3 overexpression in bladder cancer tissues was associated with poor overall survival of patients ( Figure 1In addition, Gαi3 overexpression also predicts poor overall survival in patients with papillary and non-papillary bladder cancer ( Figure 1 J and K). TCGA-BLCA Gαi3 expression data were used for receiver operating characteristic (ROC) curve analysis. The area under the curve (AUC) was 0.640, indicating that Gαi3 overexpression may be used as a diagnostic marker for bladder cancer ( Figure 1 For distinguishing high-grade from low-grade bladder cancer, the AUC obtained by ROC analysis was 0.744 ( Figure 1 In addition, the AUC for diagnosing papillary and non-papillary bladder cancer was 0.621 ( Figure 1 (in N).

[0080] 3.2 Single-cell sequencing shows that Gαi3 is overexpressed in bladder cancer epithelial cells

[0081] Further bioinformatics analysis was performed on the GEO single-cell dataset GSE222315, which includes bladder cancer (BLCA) and control normal bladder samples (“NORM”). The dimensionality reduction plot shows the cell annotation ( Figure 2 A), revealing that Gαi3 is expressed in various cell populations in bladder cancer and control samples ( Figure 2 Middle B). Dot plot analysis showed that Gαi3 was highly expressed in epithelial cell populations and myeloid immune cell populations ( Figure 2 Compared with the NORM group, the expression of Gαi3 in the epithelial cell population in the BLCA group was significantly increased ( Figure 2 (middle D).

[0082] Epithelial cells were further extracted and divided into Gαi3 positive (Gαi3 positive) and Gαi3 positive (Gαi3 + ) and Gαi3 negative (Gαi3 - ) cell population( Figure 2 Middle E). + and Gαi3 - The differential analysis of the groups was performed to identify differentially expressed genes (DEGs) with p value < 0.05 and log2FC > 1. Subsequent Gene Ontology (GO) analysis showed that DEGs were enriched in pathways related to STAT protein phosphorylation activation, tyrosine phosphorylation, negative regulation of Th-17 immune function and differentiation, and epithelial cell migration ( Figure 2 In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that these DEGs were associated with cytokine and receptor interactions, Th1 and Th2 cell differentiation, JAK-STAT signaling pathway, Akt-mTOR signaling pathway, and TGF-β signaling pathway ( Figure 2 Middle G).

[0083] 3.3Gαi3 is overexpressed in human bladder cancer tissues and cells

[0084] The present invention also detected the expression of Gαi3 in locally treated human bladder cancer tissue. A total of 12 patients who underwent bladder tumor resection were included in the present invention. As described above, cancer tissue ("T") and adjacent normal bladder tissue ("N") were separated. Part of the tissue sample was homogenized using tissue lysis buffer. The results showed that the level of Gαi3 mRNA in cancer tissue was more than 3 times higher than that in normal tissue ( Figure 3 In addition, in 4 representative patients ("T1 / T2 / T3 / T4", Figure 3 Elevated levels of Gαi3 protein were observed in cancer tissues of patients with leukemia (B), whereas normal tissues from the same patients showed relatively low expression (“N1 / N2 / N3 / N4”, Figure 3 Middle B). The summary of the western blot data of all 12 groups of tissues showed that Gαi3 protein was significantly upregulated in bladder cancer tissues ( Figure 3 Immunohistochemistry (IHC) staining also confirmed that the expression of Gαi3 protein was increased in "T1 / T2" cancer tissues, while the expression in "N1 / N2" normal tissues was relatively low ( Figure 3 Middle D). Quantified IHC scores summarized the results of all 12 tissue pairs and further confirmed that Gαi3 protein was significantly upregulated in bladder cancer tissues ( Figure 3 (middle D).

[0085] At the same time, the present invention detected the expression of Gαi3 in human bladder cancer cells. The data showed that Gαi3 mRNA was expressed in primary (priBlCa-1 / priBlCa-2 / priBlCa-3) and T24 immortalized cancer cells ( Figure 3 E) were significantly increased in bladder epithelial cells, while the expression levels were low in priBEC-1 and priBEC-2 bladder epithelial cells ( Figure 3 In addition, Gαi3 protein was upregulated in both primary and immortalized bladder cancer cells, whereas pribec-1 and pribec-2 epithelial cells expressed lower levels ( Figure 3 (F) Therefore, Gαi3 is overexpressed in human bladder cancer tissues and cells.

[0086] 3.4Gαi3shRNA has a significant anti-tumor effect in bladder cancer cells

[0087] To investigate the functional role of Gαi3 in bladder cancer cells, the expression of Gαi3 was silenced using shRNA-mediated technology. Human primary bladder cancer cells priBlCa-1 were transfected with three different lentiviral shRNAs targeting Gαi3: shGαi3-S1, shGαi3-S2, and shGαi3-S3. After puromycin selection, stable cells were generated and cultured. qPCR assays showed that Gαi3 mRNA levels were significantly reduced by more than 80% ( 100 ng / ml) in priBlCa-1 cells expressing shGαi3-S1, shGαi3-S2, or shGαi3-S3 compared with the control group transfected with scrambled shRNA (shC). Figure 4 Middle A). The mRNA levels of Gαi1 and Gαi2 remained unchanged ( Figure 4 Western blot analysis confirmed that Gαi3 protein was effectively silenced in stable priBlCa-1 cells, while Gαi1 and Gαi2 protein levels were not affected ( Figure 4 (middle B).

[0088] The viability of priBlCa-1 cells was significantly reduced after Gαi3 knockout as determined by CCK-8. Figure 4 In addition, in priBlCa-1 cells expressing shGαi3, cell proliferation was significantly reduced, as evidenced by a decrease in the proportion of EdU-stained nuclei ( Figure 4 In addition, the "Transwell" experiment showed that Gαi3 shRNA inhibited the migration of priBlCa-1 cells in vitro ( Figure 4 E) and invasion ( Figure 4 As expected, shC did not significantly alter the expression of Gαi1, Gαi2, or Gαi3 ( Figure 4 A and B), nor did it significantly change the functional properties of bladder cancer cells ( Figure 4 (in CF).

[0089] Subsequent experiments were designed to determine whether Gαi3 silencing would produce similar effects in other bladder cancer cell lines. Primary human bladder cancer cells priBlCa-2 and priBlCa-3 from two additional patients, as well as the immortalized bladder cancer cell line T24, were stably transduced with lentiviral Gαi3 shRNA ("shGαi3-S3"). The results showed that Gαi3 mRNA was significantly downregulated in both primary and immortalized bladder cancer cells ( Figure 4 G), but did not affect the level of Gαi1 mRNA ( Figure 4 In primary bladder cancer cells and T24 cell lines, knockdown of Gαi3 resulted in a significant decrease in cell proliferation and a decrease in the proportion of EdU-positive nuclei ( Figure 4Meanwhile, the “transwell” assay showed that cell migration was inhibited ( Figure 4 (in Chinese).

[0090] In addition, shGαi3-S3 transduced primary bladder epithelial cells priBEC-1 and priBEC-2. This resulted in a significant decrease in Gαi3 mRNA expression ( Figure 4 medium K), but did not affect the level of Gαi1 mRNA ( Figure 4 Unlike bladder cancer cells, silencing Gαi3 in these epithelial cells by shGαi3-S3 did not inhibit cell proliferation, as demonstrated by EdU assay ( Figure 4 M), and CCK-8 detected that the cell viability was not affected ( Figure 4 In conclusion, Gαi3 shRNA has a significant anti-tumor effect on bladder cancer cells.

[0091] 3.5Gαi3shRNA induces apoptosis and activation of bladder cancer cells

[0092] Considering that knockdown of Gαi3 using shRNA inhibits the proliferation of primary and established bladder cancer cells ( Figure 4 ), the present invention aims to explore its potential role in inducing cell apoptosis. It is worth noting that in priBlCa-1 cells stably expressing shGαi3-S1, shGαi3-S2 and shGαi3-S3, caspase-3 activity was significantly increased ( Figure 5 Further Western blot analysis showed that Gαi3 shRNA induced the cleavage of caspase-3 and poly (ADP-ribose) polymerase 1 (PARP-1) in priBlCa-1 cells ( Figure 5 In B), indicating the initiation of cell apoptosis. To support this observation, the present invention detected that gαi3 shRNA significantly increased the histone-bound DNA content in gαi3-silenced priBlCa-1 cells ( Figure 5 C) and cytosolic cytochrome C levels ( Figure 5 In addition, accumulation of JC-1 green monomers supports mitochondrial depolarization in gαi3-deficient priBlCa-1 cells ( Figure 5 This was further confirmed by the increase in TUNEL-positive nuclei in priBlCa-1 cells treated with shGαi3-S1, shGαi3-S2, and shGαi3-S3 ( Figure 6 In addition, FACS analysis showed that the proportion of Annexin-V-positive priBlCa-1 cells increased after Gαi3 knockdown ( Figure 6In contrast, shC did not trigger apoptosis in priBlCa-1 cells ( Figure 5 Medium AF and Figure 6 (middle D).

[0093] Similar results were observed in other primary bladder cancer cells (priBlCa-2 and priBlCa-3) and in the immortalized T24 cell line. Silencing of Gαi3 using shGαi3-S3 (see Figure 4 ) resulted in a significant increase in caspase-3 activity ( Figure 6 In addition, in these bladder cancer cells expressing shGαi3-S3, apoptosis was significantly activated, and TUNEL-positive nuclear staining increased significantly ( Figure 6 In contrast, silencing of Gαi3 in bladder epithelial cells priBEC-1 and priBEC-2 by shGαi3-S3 did not result in activation of apoptosis, as evidenced by the slight changes in the proportion of TUNEL-positive nuclei ( Figure 6 Middle C). These results indicate that Gαi3 silencing induces apoptosis activation in bladder cancer cells.

[0094] 3.6Gαi3 knockout hinders the progression of bladder cancer cells

[0095] In order to further confirm the key function of Gαi3 in bladder cancer cells, the present invention uses CRISPR / Cas9 gene editing technology to achieve complete knockout (KO) of Gαi3. After the CRISPR / Cas9-Gαi3-KO-puro construct was introduced into the priBlCa-1 primary cells expressing cas9, two single stable clones, "koGαi3-C1" and "koGαi3-C2", were successfully established by screening Gαi3 KO. As shown in the figure, the expression of Gαi3 protein in koGαi3-C1 and koGαi3-C2 priBlCa-1 cells was completely absent, while the expression levels of Gαi1 and Gαi2 proteins were not affected ( Figure 7 Middle A). After CRISPR / cas9-mediated Gαi3 KO, the proliferation of priBlCa-1 cells was inhibited and the EdU staining of the nucleus was significantly reduced ( Figure 7 In addition, the results of the "Transwell" experiment showed that after Gαi3 KO, the in vitro migration of priBlCa-1 cells ( Figure 7 C) and invasion ( Figure 7 The observed accumulation of JC-1 green monomers further supports the hypothesis that mitochondrial depolarization in koGαi3-C1 and koGαi3-C2priBlCa-1 cells ( Figure 7In addition, apoptosis activation of ko-Gαi3 priBlCa-1 cells was confirmed, and the proportion of TUNEL-positive nuclei increased significantly ( Figure 7 Middle F).

[0096] In bladder epithelial cells pribec-1 and pribec-2, the same CRISPR / Cas9-Gαi3-KO-puro construct was used to generate Gαi3KO epithelial cells, named "koGαi3". Compared with the control epithelial cells koC, Gαi3 protein was completely unexpressed in koGαi3 priBEC-1 and pribec-2 cells ( Figure 7 G). The expression of Gαi1 protein remained almost unchanged ( Figure 7 Unlike the results observed in cancer cells, KO of Gαi3 did not reduce the viability of epithelial cells (verified by CCK-8 OD, Figure 7 H), nor did it affect the proliferation of epithelial cells (assessed by nuclear EdU assay, Figure 7 Taken together, these findings underscore the indispensable role of Gαi3 in the progression of bladder cancer cells and highlight its potential as a therapeutic target.

[0097] 3.7. Gαi3 overexpression enhances the oncogenic behavior of bladder cancer cells

[0098] Given the potent anti-bladder cancer effects of Gαi3 after silencing or KO, it was hypothesized that overexpression of Gαi3 might exert pro-tumor properties. To investigate this, a lentiviral-mediated gαi3 overexpression construct (referred to as "oeGαi3") was introduced into priBlCa-1 primary bladder cancer cells. After puromycin selection, two stable cell screens, "oeGαi3-stbslc1" and "oeGαi3-stbslc2", were established. qPCR and Western Blotting assays confirmed that Gαi3 mRNA and protein levels were significantly upregulated in these priBlCa-1 cells expressing oeGαi3 compared with cells transduced with a lentiviral empty vector (Vec). The expression levels of Gαi1 and Gαi2 remained unchanged ( Figure 8 A and B).

[0099] Overexpression of Gαi3 in priBlCa-1 cells resulted in enhanced cell proliferation and increased nuclear EdU incorporation ( Figure 8 In addition, the “Transwell” assay showed that in priBlCa-1 cells expressing oeGαi3, cell migration ( Figure 8 D) and invasion ( Figure 8These tumor-promoting effects were consistently observed in other primary bladder cancer cells (priBlCa-2 and priBlCa-3) as well as in the immortalized T24 bladder cancer cell line. Overexpression of Gαi3 in bladder cancer cells by a Gαi3 overexpression construct (“oeGαi3”) resulted in a significant increase in Gαi3 mRNA levels ( Figure 8 F), but did not affect Gαi1 mRNA expression ( Figure 8 This upregulation of Gαi3 is associated with enhanced cell proliferation ( Figure 8 Middle H) and migration ( Figure 8 This suggests that Gαi3 may play a role in promoting the oncogenic behavior of bladder cancer cells.

[0100] 3.8. Gαi3 plays an important role in Akt-mTOR activation in bladder cancer cells

[0101] In priBlCa-1 cells, silencing of Gαi3 by shGαi3-S1, shGαi3-S2, or shGαi3-S3 resulted in decreased phosphorylation of Akt at Ser-473 and S6K at Thr-389, whereas the total levels of Akt1 and S6K proteins remained unchanged ( Fig. 9 In addition, CRISPR-sgRNA-mediated KO of Gαi3 significantly reduced Akt-mTOR activation and Akt-S6K phosphorylation in koGαi3-C1 and koGαi3-C2 priBlCa-1 cells ( Fig. 9 B), but did not change the total expression of Akt1 and S6K ( Figure 8 In contrast, overexpression of Gαi3 in priBlCa-1 cells, labeled “oeGαi3-stb slc1” and “oeGαi3-stb slc2”, resulted in enhanced Akt-S6K phosphorylation ( Fig. 9 Middle C). These findings highlight the critical role of Gαi3 in regulating Akt-mTOR signaling in bladder cancer cells.

[0102] To elucidate the connection between Gαi3-induced bladder cancer cell growth and Akt-mTOR pathway activation, the present invention introduced a constitutively active Akt1 mutant (S473D, referred to as caAkt1) into gαi3-silenced priBlCa-1 cells by stable transduction ("shGαi3-S3"). The results showed that caAkt1 completely restored the phosphorylation level of Akt-S6K without affecting the expression of Gαi3 protein in priBlCa-1 cells ( Fig. 9 Furthermore, caAkt1 significantly alleviated the effects of Gαi3 silencing and nearly reversed the observed cell proliferation ( Fig.10Middle A), Migration ( Fig.10 B) and reduced apoptosis ( Fig.10 These observations suggest that activation of the Akt-mTOR signaling pathway is an important mechanism by which Gαi3 promotes the growth and survival of bladder cancer cells.

[0103] Silencing of 3.9Gαi3 impedes the growth of primary bladder cancer xenografts in nude mice

[0104] To investigate the critical role of Gαi3 in the in vivo growth of bladder cancer cells, 5 million priBlCa-1 cells expressing shGαi3-S3 or shC were subcutaneously injected into nude mice. Observation began 10 days after cell inoculation ("Day 10"). The resulting tumor growth curve, in which tumor volume was recorded every 6 days ("Day 10" to "Day 52"), showed that the growth of priBlCa-1 expressing shGαi3-s3 was significantly reduced compared to xenografts expressing shC ( Fig.11 Quantification of daily growth rate further confirmed substantial inhibition of tumor progression in priBlCa-1 xenografts expressing shGαi3-s3 ( Fig.11 (B). On day 52, all tumors were isolated and weighed. The body weight of shGαi3-S3 priBlCa-1 xenografts was significantly lower than that of Cas9-CpriBlCa-1 xenografts ( Fig.11 C), while the overall body weight of the two groups of mice was similar ( Fig.11 In shGαi3-S3priBlCa-1 xenografts, Gαi3 mRNA and protein expression was significantly reduced, while Gαi1 expression levels remained unchanged ( Fig.11 E and F).

[0105] Further studies found that in shGαi3-S3 priBlCa-1 xenograft tissues, the phosphorylation levels of Akt and S6K1 were significantly decreased ( Fig.11 In addition, immunohistochemical images confirmed the reduction of Akt phosphorylation levels in shGαi3-S3 priBlCa-1 xenograft sections ( Fig.11 Middle H). Ki-67 staining in the nuclei of Gαi3-silenced priBlCa-1 xenograft tissues was significantly reduced, indicating that proliferation was inhibited ( Fig.11 In contrast, the levels of cleaved-caspase-3 and cleaved-PARP-1 were significantly increased in priBlCa-1 xenograft tissues expressing shGαi3-s3 ( Fig.11To further confirm the induction of apoptosis, tissue fluorescence staining analysis showed that the proportion of TUNEL-positive nuclei in shGαi3-S3 priBlCa-1 xenograft tissue sections was high ( Fig.11 (middle K). Taken together, these findings indicate that silencing of Gαi3 significantly impedes the growth of priBlCa-1 xenografts in nude mice, inactivates the Akt-mTOR signaling pathway, and induces apoptosis.

[0106] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of inhibitors of the Gαi3 gene in the preparation of drugs for preventing and / or treating bladder cancer.

2. The use according to claim 1, characterized in that The inhibitor of the Gαi3 gene is selected from shRNA specific to the Gαi3 gene.

3. The use according to claim 1, characterized in that The medicine comprises a pharmaceutically acceptable carrier and an effective amount of active ingredients, and the active ingredients are inhibitors of the Gαi3 gene.

4. A drug for preventing and / or treating bladder cancer, characterized in that: The drug comprises a pharmaceutically acceptable carrier and an effective amount of a Gαi3 gene inhibitor, and the Gαi3 gene inhibitor is selected from shRNA specific to the Gαi3 gene.

5. Application of Gαi3 gene as a bladder cancer biomarker in the preparation of bladder cancer diagnostic kit or diagnostic reagent.

6. The use according to claim 5, characterized in that The diagnostic kit or diagnostic reagent comprises a primer pair for detecting the Gαi3 gene.

7. A kit for diagnosing bladder cancer, characterized in that: The kit comprises a reagent for detecting the Gαi3 gene.

8. The kit according to claim 7, characterized in that The reagents include a primer pair for amplifying the Gαi3 gene.

9. Use of a reagent for detecting the expression of the Gαi3 gene in the preparation of an auxiliary diagnostic reagent for bladder cancer, characterized in that: The reagent for detecting the expression level of the Gαi3 gene includes a primer pair for detecting the Gαi3 gene.

10. An in vitro method for inhibiting bladder cancer cells for non-therapeutic purposes, characterized in that: The following steps are involved: In the presence of an inhibitor of the Gαi3 gene, bladder cancer cells are cultured to inhibit the proliferation and growth of bladder cancer cells; the inhibitor of the Gαi3 gene is selected from shRNA specific to the Gαi3 gene.

Citation Information

Cited By

  • Application of NOTCH3 as target in preparation of pharmaceutical composition for treating bladder cancer

    CN119424651A